Sputnik Light has also been approved in San Marino as a booster shot for all vaccines administered in the country
Moscow, November 23, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) today announced the Russian one-shot Sputnik Light vaccine against coronavirus has been approved by the Government of the Republic of San Marino.
Sputnik Light vaccine is based on human adenovirus serotype 26, which is the first component of the Sputnik V vaccine. The single-dose vaccine has also been approved in San Marino as a booster shot for all vaccines administered in the country.
One-shot Sputnik Light is a highly effective vaccine when used both on standalone basis and applied as a booster. The latest findings by the Gamaleya Center based on data from 28,000 subjects in Moscow have demonstrated Sputnik Light vaccine administered standalone has 70% efficacy against infection from the Delta variant of coronavirus during the first three months after vaccination. The vaccine is 75% effective among subjects under the age of 60.
Efficacy of one-shot Sputnik Light as a booster against Delta variant for other vaccines will be close to the efficacy against the Delta variant of the Sputnik V vaccine: over 83% against infection and over 94% against hospitalization.
A one-shot vaccination regimen of Sputnik Light vaccine against coronavirus has a number of key advantages, including ease of administering the vaccine, monitoring and more flexible re-vaccination schedule when used as a booster.
Sputnik Light has demonstrated a superior efficacy compared with some two-shot vaccines, which have shown a major decline in efficacy against the Delta variant to less than 50% five months after injection. Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations.
Sputnik Light has been proven to be safe and highly effective by real-world vaccination data. In particular, the vaccine has demonstrated efficacy of between 78.6-83.7% among the elderly as confirmed by the Ministry of Health of Buenos Aires, Argentina. Paraguay’s Ministry of Health also found Sputnik Light to be 93.5% effective during the country’s ongoing vaccination campaign.
Regulatory authorities of San Marino have also authorized the two-dose Sputnik V vaccine. It has helped San Marino to become the first country in Europe to defeat COVID and start lifting COVID restrictions.
Overall efficacy of first vaccine COVID 19 RDIF Sputnik V over 21 days after administering the first dose was estimated at 94.8% while efficacy against hospitalizations estimated at 95.9% (the best efficacy against hospitalizations with COVID-19 in the country among all vaccines used).
The Russian vaccine is demonstrating high safety profile with data published in EClinicalMedicine (an open access clinical journal published by The Lancet, one of the world's most respected medical journals). In particular, Sputnik V shows high tolerability profile in ≥60 age group with nearly all reported adverse events following immunization being mild or moderate and lasting less than 2 days.
***
Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling RUB 2.1tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 1 mn people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn. Further information can be found at rdif.ru
For additional information contact:
Alexey Urazov Russian Direct Investment Fund Director for External Communications Mobile: +7 915 312 76 65 E-mail: [email protected]
Andrew Leach / Maria Shiryaevskaya Hudson Sandler Tel: +44 (0) 20 7796 4133
Message has been successfully sent!
